Overview

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
Phase:
Phase 4
Details
Lead Sponsor:
Horizon Pharma Ireland, Ltd., Dublin Ireland
Treatments:
Esomeprazole
Naproxen